- Postdiagnosis statin use is associated with a 12% reduction in contralateral breast cancer (CBC) risk in patients with nonmetastatic breast cancer.
- Patients with estrogen receptor (ER)-negative breast cancer benefit even more.
Why this matters
- Findings are consistent with earlier epidemiological studies and experimental studies.
- Findings suggest that clinicians should consider prescribing statins for CBC prevention, especially in ER− patients.
- Retrospective cohort of 57,723 women with nonmetastatic breast cancer from the Danish Breast Cancer Group database.
- Postdiagnosis statin use was defined by a minimum of 2 prescriptions 1 year apart.
- Funding: Danish Cancer Society; private foundations.
- Follow-up was 310,537 person-years.
- Postdiagnosis statin use (vs never-use) was associated with a 12% lower CBC risk (HR, 0.88; 95% CI, 0.73-1.05); current statin use had similarly lower risk (HR, 0.87; 95% CI, 0.72-1.04).
- Long-term postdiagnosis statin use overall was associated with a 36% lower CBC risk (HR, 0.64; 95% CI, 0.43-0.96), but not long-term consistent use or high-intensity use (HR, 0.95; 95% CI, 0.55-1.64).
- Among patients with ER− breast cancer, postdiagnosis statin use was associated with a 33% lower CBC risk (HR, 0.67; 95% CI, 0.45-1.00).
- Retrospective, observational design.
- No information on compliance or other drug use.